Evidence map›Paper›PMID 37144078›Full record

ArticleIJU case reports2023

Hajime Takamori, Akiko Miyagi Maeshima, Ikuma Kato, Masaya Baba, Eijiro Nakamura, Yoshiyuki Matsui

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Cancers · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Hajime TakamoriDepartment of Urology National Cancer Center Hospital Tokyo Japan.ORCID https://orcid.org/0000-0001-5118-4071
Akiko Miyagi MaeshimaDepartment of Diagnositic Pathology National Cancer Center Hospital Tokyo Japan.
Ikuma KatoDepartment of Molecular Pathology Yokohama City University Graduate School of Medicine Yokohama Japan.
Masaya BabaInternational Research Center for Medical Sciences Kumamoto University Kumamoto Japan.
Eijiro NakamuraDepartment of Urology National Cancer Center Hospital Tokyo Japan.
Yoshiyuki MatsuiDepartment of Urology National Cancer Center Hospital Tokyo Japan.
Tokyo National Hospital · JPKumamoto Medical Center · JPNational Cancer Centre Japan · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Renal cell carcinoma with Case presentation: A 70-year-old man was referred to our institution for the treatment of renal cell carcinoma with multinodal metastases. Open nephrectomy and lymph node dissection were performed. Immunohistochemistry for transcription factor EB was positive, and fluorescent in situ hybridization revealed Conclusion: A good long-term response to anti-vascular endothelial growth factor drug therapy may be due to

Indexed as

carcinoma, renal cellgene amplificationin situ hybridization, fluorescencetranscription factorsvascular endothelial growth factor A

Identifiers

PMID37144078
PMCPMC10151203
OpenAlexW4322772547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.